THE QUESTIONS THAT NEED TO BE ASKED

If successful, will other colleges and universities follow the model developed at URI with MindImmune to embed for-profit research firms into the university enterprise? How will the identity of a biomarker in neuro-inflammation diseases change the treatments for Parkinson’s, MS, and other auto-immune diseases? What kinds of investment will the state of Rhode Island be willing to make to secure MindImmune’s continued location in Rhode Island?